Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
- PMID: 18395777
- DOI: 10.1016/j.ygyno.2008.02.006
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
Abstract
Objective: To compare the clinico-pathologic characteristics and survival of women with clear cell versus other epithelial ovarian cancers.
Methods: Data were obtained from the Surveillance, Epidemiology and End Results Program between 1988 and 2001 and analyzed using Kaplan-Meier and Cox proportional hazards models.
Results: Of 28,082 women with epithelial ovarian cancer, 1411 (5%) had clear cell, 13,835 (49.3%) papillary serous, 3655 (13%) endometrioid, 2711 (9.7%) mucinous, and 6470 (23%) had unspecified histologies. The median age of overall patients was 64 years; with clear cell patients presenting at younger age (55 years). The proportion of clear cell histology was significantly higher in Asians versus Whites, Blacks, and others (11.1% versus 4.8%, 3.1%, and 5.5%; p<0.001). Clear cell carcinoma is more likely to be diagnosed at early-stage (67.3%) compared to 19.2% in serous, 61.6% endometrioid, and 61.3% in mucinous carcinomas (p<0.005). Retroperitoneal lymph node metastases were found in 13.6% of serous carcinomas, 7.9% clear cell, 7.3% endometrioid, and 3.8% of mucinous (p<0.001). Adjusted for stage, the 5-year disease-specific survival of patients with clear cell carcinoma is worse compared to serous: 85.3% vs. 86.4% for stage I, 60.3% vs. 66.4% stage II, 31.5% vs. 35.0% stage III, and 17.5% vs. 22.2% for stage IV, respectively (p<0.001). On multivariate analysis, age, stage, grade, histology, and surgical treatment were independent predictors of disease-specific survival.
Conclusions: Our data suggest that women with clear cell ovarian cancer present at a younger age, are more likely to be Asian, and have a poorer prognosis compared to serous cancers.
Similar articles
-
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390. Cancer. 2008. PMID: 18348296 Clinical Trial.
-
Association of lymphadenectomy and survival in stage I ovarian cancer patients.Obstet Gynecol. 2007 Jan;109(1):12-9. doi: 10.1097/01.AOG.0000249610.95885.ef. Obstet Gynecol. 2007. PMID: 17197582
-
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.Gynecol Oncol. 2000 Apr;77(1):55-65. doi: 10.1006/gyno.2000.5737. Gynecol Oncol. 2000. PMID: 10739691
-
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.Gynecol Oncol. 2004 Aug;94(2):456-62. doi: 10.1016/j.ygyno.2004.05.006. Gynecol Oncol. 2004. PMID: 15297188 Review.
-
Histological classification of ovarian cancer.Med Electron Microsc. 2003 Mar;36(1):9-17. doi: 10.1007/s007950300002. Med Electron Microsc. 2003. PMID: 12658347 Review.
Cited by
-
Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.BMC Cancer. 2024 Nov 14;24(1):1403. doi: 10.1186/s12885-024-13125-5. BMC Cancer. 2024. PMID: 39543535 Free PMC article.
-
SOX17 expression in ovarian clear cell carcinoma.J Ovarian Res. 2024 Nov 11;17(1):221. doi: 10.1186/s13048-024-01549-3. J Ovarian Res. 2024. PMID: 39529086 Free PMC article.
-
The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre.Transl Cancer Res. 2024 Sep 30;13(9):5037-5049. doi: 10.21037/tcr-24-83. Epub 2024 Sep 11. Transl Cancer Res. 2024. PMID: 39430857 Free PMC article.
-
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.Cancers (Basel). 2024 Sep 3;16(17):3068. doi: 10.3390/cancers16173068. Cancers (Basel). 2024. PMID: 39272926 Free PMC article. Review.
-
Comparing Four Different Risk Malignancy Indices in Differentiating Benign and Malignant Ovarian Masses.J Midlife Health. 2024 Apr-Jun;15(2):75-80. doi: 10.4103/jmh.jmh_192_23. Epub 2024 Jul 5. J Midlife Health. 2024. PMID: 39145276 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical